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Background: Recent studies have revealed that the splicing factor neuro-oncological ventral anti-
gen 1 (NOVA1) is enriched in fibroblasts and accumulated T cells of tertiary lymphoid structures. 
In the present study, we investigated NOVA1 expression in various subtypes of mature and im-
mature T- and natural killer (NK)-cell lymphomas as well as in various B-cell lymphoma subtypes. 
Methods: NOVA1 immunoexpression was evaluated in hyperplastic palatine tonsils (n = 20), T- 
and NK-cell lymphomas (n = 177), diffuse large B-cell lymphomas (n = 151), and other types of B 
cell lymphomas (n = 31). Nuclear staining intensity and percentage of positive tumor cells were 
graded. NOVA1 mRNA expression was analyzed in various lymphoma cell lines. Results: Tumor 
cells of T- and NK-cell lymphomas showed higher expression levels of NOVA1 than did normal 
paracortical T cells, and 56.5% of T- and NK-cell lymphoma cases showed diffuse and strong 
expression. The NOVA1 expression level varied according to the subtype; it was higher in angio-
immunoblastic T-cell lymphoma, anaplastic lymphoma kinase (ALK)-negative anaplastic large cell 
lymphoma (ALCL), and T lymphoblastic leukemia/lymphoma (T-LBL), but it was lower in ALK-
positive ALCL. In almost all B-cell lymphomas, NOVA1 expression was very low or negative. 
NOVA1 mRNA was also expressed in Jurkat, a T-LBL cell line. Conclusions: The present findings 
suggest that NOVA1 upregulation may be involved in certain subtypes of T- and NK-cell lympho-
mas, but not in B-cell lymphomas. Upregulated NOVA1 expression seems to be a specific bio-
logical feature of activated T cells such as T- and NK-cell lymphomas.
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▒ ORIGINAL ARTICLE ▒
Neuro-oncological ventral antigen 1 (NOVA1) is known to 
play a role in the neuronal splicing program.1-4 A recent study 
revealed that the splicing programs of epithelial cells, fibro-
blasts, and endothelial cells are specifically regulated by the epi-
thelial splicing regulatory protein 1 (ESRP1) and ESRP2, muscle 
blind-like splicing regulator 1 (MBNL1), NOVA1, and polypy-
rimidine tract binding protein 1 (PTBP1). Furthermore, RNA 
binding protein, fox-1 homolog 2 (RBFOX2) splicing factors, 
and NOVA1 are found enriched in fibroblasts.5 In our recent 
study,6 we also confirmed that NOVA1 is highly expressed in 
fibroblasts/stromal spindle cells in normal tissues.
In addition, we observed that NOVA1 is frequently upregu-
lated in accumulated T lymphocytes in tertiary lymphoid struc-
tures formed by chronic inflammation, whereas only small num-
bers of T lymphocytes express NOVA1 in the secondary lymphoid 
organs, such as hyperplastic palatine tonsils.6-8 These findings 
suggest that NOVA1 upregulation may be involved in T cell ac-
tivation and proliferation.6 Given that fibroblasts/stromal spin-
dle cells actively regulate immune cells within the tissue micro-
environment through direct interaction with immune B cells or 
T cells,9,10 NOVA1-related regulation in stromal fibroblasts/spin-
dle cells may also occur in immune cells. 
We hypothesized that NOVA1 upregulation could be involved 
in the pathogenesis of malignant lymphoma, which is a neo-
plasm of activated or transformed immune cells. In our previous 
study, peripheral T-cell lymphoma cases frequently showed 
strong NOVA1 expression while mature B-cell lymphoma cases 
did not,6 although the investigation was done on a small scale. 
In the present study, we extended our study to confirm the role 
of NOVA1 in the pathogenesis of malignant lymphoma. We 
thoroughly investigated NOVA1 expression in a large number of 
various subtypes of mature and immature T- and natural killer 
(T/NK)-cell lymphomas, and the expression of NOVA1 was 
also compared in various subtypes of B-cell lymphomas.
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MATERIALS AND METHODS
Patients and clinical data
Archival tissues of formalin-fixed, paraffin-embedded (FFPE) 
tumor blocks were retrieved from consecutively archived speci-
mens. A set of 177 T/NK-cell lymphomas diagnosed in Sever-
ance Hospital from 1999 to 2013 were included. The subtypes 
of T/NK-cell lymphomas were as follows: extranodal NK/T-cell 
lymphoma, nasal type (NKTL; n = 60), peripheral T-cell lym-
phoma, not otherwise specified (PTCL-NOS; n = 44), angioim-
munoblastic T-cell lymphoma (AITL; n = 16), anaplastic large 
cell lymphoma (ALCL; anaplastic lymphoma kinase [ALK]-
positive, n = 16; ALK-negative, n = 17), T lymphoblastic leuke-
mia/lymphoma (T-LBL; n = 20) and other types (n = 4; hepato-
splenic T-cell lymphoma, n = 2; subcutaneous panniculitis-like 
T-cell lymphoma, n = 1; cutaneous gamma-delta T-cell lympho-
ma, n = 1). Clinical information was obtained from patient 
medical records and 139 had clinical data available. The clini-
copathological characteristics are summarized in Appendix 1. 
A set of 151 diffuse large B cell lymphoma (DLBCL) and other 
types of 31 B-cell lymphomas, which were diagnosed in Sever-
ance Hospital from 2005 to 2011, were included. Other types of 
B-cell lymphomas were as follows: follicular lymphoma (n = 14), 
mantle cell lymphoma (n = 5), marginal zone B-cell lymphoma 
(n = 7), and Burkitt lymphoma (n = 5). Hyperplastic palatine 
tonsil tissues of cancer-free individuals (n = 20) were randomly 
retrieved. All tumor samples were reviewed by hematopatholo-
gists based on the current World Health Organization (WHO) 
criteria.11 The institutional review board approved this study. 
Tissue microarray preparation and immunohistochemistry
Sections of FFPE tissues were prepared and stained with he-
matoxylin and eosin. Under the microscope, the representative 
area was confirmed and selected for a 3-mm-core sized tissue 
microarray (TMA). One or two different representative areas per 
case were selected and 29 cores were embedded in a TMA block. 
Immunohistochemistry of NOVA1 (1:500, Abcam, Cam-
bridge, UK) was performed on 4-μm tissue sections using the 
Ventana BenchMark XT Autostainer (Ventana Medical Systems, 
Tucson, AZ, USA). Immunohistochemistry with other primary 
antibodies was performed for diagnostic purposes and the tested 
antibodies are listed in Appendix 2.
 
Analysis of immunohistochemistry
NOVA1 expression was semiquantitatively determined accord-
ing to the H-score method with a total score range of 0–300.12 
The dominant intensity score of nuclear staining (0, absent; 1, 
weak or barely detectable; 2, distinct brown; and 3, strong dark 
brown) was multiplied by the percentage of positive tumor cell 
nuclei. The NOVA1 protein expression score ranged from 0 to 
300, as high (200 < H-score ≤ 300), intermediate (100 < H-score 
≤ 200), or low (0 ≤ H-score ≤ 100) expression.
Cell lines and reagents
Jurkat, a T-LBL cell line, was maintained in RPMI1640 medi-
um (22400-089, Gibco, Life Technologies, Carlsbad, CA, USA) 
supplemented with 10% heat-inactivated fetal bovine serum 
(FBS; 6000-044, Gibco, Life Technologies). HH, a cell line de-
rived from CD30-positive cutaneous T-cell lymphoma, and 
MAC1, a cell line derived from CD30-positive ALK-negative 
ALCL, were maintained in RPMI1640 medium supplemented 
with 20% heat-inactivated FBS. SNK6, derived from Epstein-
Barr virus (EBV)-positive NKTL, was cultured in RPMI1640 
medium supplemented with 10% heat-inactivated human plas-
ma and 700 U/mL of recombinant interleukin 2. YT, an EBV-
positive human NK-like leukemic cell line, was cultured in Is-
cove’s modified Dulbecco’s medium (12440-046, Gibco) 
supplemented with 20% heat-inactivated FBS. All the cell lines 
derived from T- or NK-cell lymphomas were kindly provided 
by Prof. Jeon YK (Seoul National University College of Medi-
cine, Seoul, Korea). Toledo, a DLBCL cell line, was purchased 
from the American Type Culture Collection (ATCC, Manassas, 
VA, USA) and maintained in RPMI1640 supplemented with 
10% heat-inactivated FBS. 
RNA isolation and quantitative polymerase chain reaction
RNA isolation was performed using an RNeasy plus mini kit 
(74134, Qiagen, Hilden, Germany), and cDNA was constructed 
using a cDNA synthesis kit (11754-050, Invitrogen, Carlsbad, 
CA, USA). The TaqMan probes used were as follows: GAPDH 
(Hs99999905-m1, AB, Life Technologies) and NOVA1 
(Hs00359592-m1, AB, Life Technologies). Quantitative poly-
merase chain reaction was performed using ABI StepOnePlus 
under the following conditions: 50°C for 2 minutes, 95°C for 5 
minutes, 40 cycles of 95°C for 15 seconds, and 60°C for min-
utes. Relative mRNA expression levels of NOVA1 were deter-
mined by the comparative method (2-ddCt) against the reference 
GAPDH.
Statistical analysis
The Kruskal-Wallis (K-W), Mann-Whitney U (M-W), t and 
χ2 tests were used to analyze differences between the variables ex-
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amined. Survival rates were analyzed with the Kaplan-Meier 
method, and differences were compared using the log-rank test. 
Two-sided p-values less than .05 were considered statistically 
significant. Statistical analyses were done using the IBM SPSS 
ver. 22 (IBM Corp., Armonk, NY, USA). 
RESULTS
Expression of NOVA1 in the palatine tonsils 
The NOVA1 expression patterns in the cell nuclei were simi-
lar to those reported in a previous study.6 Stromal spindle cells/
fibroblasts showed strong and constant expression of NOVA1. 
Endothelial cells variably expressed NOVA1 with negative to 
moderate intensity. Almost all B cells of the germinal centers or 
outside the germinal centers were negative for NOVA1. As for 
T cells, occasional expression of NOVA1 (intensity grade 2–3 
with 5% or less percentage of T cells) was noted in the paracor-
tical area (Table 1). 
Expression of NOVA1 in T/NK-cell lymphomas
T/NK-cell lymphomas showed low to high NOVA1 expres-
sion and 99 (56.5%) showed high NOVA1 expression (Table 1, 
Fig. 1). The expression level (score) of NOVA1 was higher in tu-
mor cells of T/NK-cell lymphomas when compared to normal 
T cells of tonsil tissues (mean score, 209 vs. 7; p < .001; non-
parametric M-W) (Fig. 2A). Within T/NK-cell lymphomas, 
precursor T-LBL showed a relatively higher level of NOVA1 
expression than did NKTL or mature (peripheral) T-cell lym-
phomas, although a statistically significant difference was not 
noted (p = .226; K-W) (Fig. 2B). According to the specific sub-
types of T/NK-cell lymphomas, the expression level of NOVA1 
in tumor cells varied (p = .011; K-W). AITL, ALK-negative 
ALCL, and T-LBL showed relatively higher NOVA1 expression 
levels when compared to other subtypes (Table 1, Fig. 2C). Spe-
cifically, ALK-positive ALCL revealed a lower level of NOVA1 
expression when compared to ALK-negative ALCL (mean score, 
156 vs. 259; p = .027; M-W) and ALK-positive ALCL showed 
the lowest expression level among subtypes of T/NK-cell lym-
phomas (Table 1, Fig. 2C). The rate of high, intermediate, or low 
expression of NOVA1 was also different according to subtype (p 
< .001); high expression was relatively more frequent in AITL, 
ALK-negative ALCL, and T-LBL cells, while low expression was 
relatively more frequent in NKTL and ALK-positive ALCL 
(Table 1, Fig. 2D).
 
Expression of NOVA1 in DLBCLs
In DLBCL, high NOVA1 expression was not noted in any cas-
es. The tested 151 DLBCL cases revealed an expression pattern 
with a score less than 10. Furthermore, in the various types of 
other B-cell lymphomas, high NOVA1 expression was not not-
ed (Table 1, Fig. 3). 
 
Table 1. NOVA1 expression in several types of normal and tumor immune cells
Tissue category Case No.
NOVA1 expression
General pattern
Frequency of expression category (%) H-score
(mean)High Intermediate Low 
Palatine tonsils 20 Small numbers of T cells 0 0 100 7
T- and NK-cell lymphomas 177 Strong and diffuse 56.5 18.6 24.9 209
NKTL 60 Lower 54.2 13.6 32.2 195
PTCL-NOS 44 Diverse 38.6 40.9 20.5 194
AITL 16 Higher 81.2 6.2 12.5 255
ALK-negative ALCL 17 Higher 82.4 5.9 11.8 259
ALK-positive ALCL 16 Lower 40 13.3 46.7 156
T-LBL 20 Higher 75 5 20 237
Other typesa 4 NA 25 50 25 175
B-Cell lymphomas 182 Almost negative 0 0 100 7
DLBCL 151 Almost negative 0 0 100 8
Other typesb 31 Almost negative 0 0 100 5
NOVA1, neuro-oncological ventral antigen 1; NK, natural killer; NKTL, extranodal natural killer/T-cell lymphoma, nasal type; PTCL-NOS, peripheral T-cell lym-
phoma, not otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; ALK, anaplastic lymphoma kinase; ALCL, anaplastic large cell lymphoma; T-LBL, 
T lymphoblastic leukemia/lymphoma; DLBCL, diffuse large B-cell lymphoma.
aThe T- or NK-cell lymphomas of the “other type” category included hepatosplenic T-cell lymphoma (n = 2), subcutaneous panniculitis-like T-cell lymphoma (n = 
1), and cutaneous gamma-delta T-cell lymphoma (n = 1). The case number for this category was too small (only 4 cases), and therefore NOVA1 expression 
may not be representative for this category; bThe set of “other type” B-cell lymphomas was composed of follicular lymphoma (n = 14), mantle cell lymphoma (n 
= 5), marginal zone B-cell lymphoma (n = 7), and Burkitt lymphoma (n = 5).
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NOVA1 gene expression in human lymphoma cell lines
NOVA1 mRNA was expressed only in the Jurkat cell line, 
which corresponds to T-LBL. NOVA1 mRNA was not detected 
in other tested cell lines of HH (correspondent to peripheral, 
mature T cell lymphoma), MAC1 (peripheral, mature T-cell 
lymphoma), SNK6 (NKTL), YT (NK cell leukemia), or Toledo 
(DLBCL) (Fig. 4). 
NOVA1 expression and its clinicopathologic correlation in 
T/NK-cell lymphomas
The NOVA1 expression level in tumor cells was not different 
according to the organ/sites where lymphomas were growing 
(Appendix 3). The known clinicopathological prognostic fac-
tors such as age, lactate dehydrogenase level, Ann-Arbor stage, 
or International Prognostic Index (IPI) risk scores showed no 
correlation with NOVA1 expression. In cases of mature (pe-
ripheral) T-cell lymphomas, high expression of NOVA1 tended 
to be related to shorter overall survival rate in comparison to 
low or intermediate NOVA1 expression, although statistical 
significance was not observed (Fig. 5A, B). In other subtypes, 
such as NKTL and T-LBL, no correlation was noted between 
NOVA1 expression and overall survival rate. 
A
D
G
B
E
H
C
F
I
Fig. 1. Representative cases of T- and natural killer (NK)-cell lymphoma. Representative cases of extranodal NK/T-cell lymphoma, nasal type 
(NKTL) are presented, which show low (A), intermediate (B), and high (C) levels of neuro-oncological ventral antigen 1 (NOVA1) expression. 
Among mature (peripheral) T-cell lymphoma cases, low to high expression of NOVA1 is variably observed (D–G). (D) A case of peripheral T cell 
lymphoma, not otherwise specified (PTCL-NOS), reveals low NOVA1 expression. A case of angioimmunoblastic T-cell lymphoma (AITL) (E) 
and a case of anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL) (F) exhibits high NOVA1 expression. A case 
of ALK-positive ALCL (G) demonstrates low NOVA1 expression. A case of precursor T lymphoblastic lymphoma/leukemia (T-LBL) (H) shows 
high NOVA1 expression while a case of T-LBL shows low NOVA1 expression. Endothelial cells exhibit high or low NOVA1 expression in accor-
dance with the NOVA1 status of tumor T cells (white arrow in panels in C and D). In cases where most tumor cells showed negative NOVA1 
expression, stromal fibroblasts (black arrow in panel I) and endothelial cells (white arrow in panel I) demonstrate positive NOVA1 expression.
NKTL
PCTL-NOS AITL ALK– ALCL
T-LBLT-LBLALK+ ALCL
NKTL NKTL
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DISCUSSION
In this study, we found that NOVA1 was frequently and high-
ly expressed in various subtypes of T/NK-cell lymphomas, with 
about 60% of T/NK-cell lymphoma cases showing high NOVA1 
expression, whereas only a small number of T cells expressed 
NOVA1 in the hyperplastic palatine tonsils. As for B-cell lym-
phomas, NOVA1 was negative in various types of B-cell lym-
phomas other than DLBCL, or normal B cells. In DLBCL, NOVA1 
was expressed in a few cases; however, high expression was not 
noted in any cases. 
Our previous study6 revealed high expression of NOVA1 in 
activated T cells and the present study also confirmed that find-
ing. Moreover, NOVA1 was upregulated in lymphomas derived 
Fig. 2. Expression level of neuro-oncological ventral antigen 1 (NOVA1) in T- and natural killer (NK) cell lymphomas and normal T cells. (A) Ex-
pression level (score) of NOVA1 is higher in tumor cells of T/NK-cell lymphomas when compared to normal T cells of tonsil tissues (mean 
score, 7 vs 209; p < .001). (B) Within T/NK-cell lymphomas, T lymphoblastic leukemia/lymphoma (T-LBL) shows relatively higher levels of 
NOVA1 expression than do extranodal NK/T-cell lymphoma, nasal type (NKTL) or mature (peripheral) T-cell lymphomas, although a statisti-
cally significant difference is not noted (p = .226). (C) According to the specific subtypes of T/NK-cell lymphomas, the expression levels of tu-
mor cells are different (p = .012). Angioimmunoblastic T-cell lymphoma (AITL), anaplastic lymphoma kinase (ALK)-negative anaplastic large 
cell lymphoma (ALCL), and T-LBL shows a relatively higher level of NOVA1 expression (arrow) when compared to other subtypes. ALK-posi-
tive ALCL reveals lower NOVA1 expression (dotted arrow) when compared to ALK-negative ALCL (mean score, 159 vs 256; p = .027) and 
ALK-positive ALCL shows the lowest expression among subtypes of T/NK cell lymphomas. (D) The rates of high, intermediate, and low ex-
pression of NOVA1 are different according to subtype (p < .001); high expression is relatively more frequent in AITL, ALK-negative ALCL, and 
T-LBL (solid arrow), while low expression is relatively more frequent in ALK-positive ALCL and NKTL (dotted arrow). The case number in the 
“others” category is too small (only 4 cases), and therefore, the NOVA1 expression may not be representative of this category. PTCL, periph-
eral T-cell lym phoma; PTCL-NOS, peripheral T-cell lym phoma, not otherwise specified.
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from immature T cells such as precursor T-LBL and NKTL. How-
ever, in contrast to T/NK cells, NOVA1 might not be involved 
in B cell lesions, either malignant lymphomas or non-neoplastic 
B cells, as shown in our studies.
Among subtypes of T/NK-cell lymphomas, the expression 
level in tumor cells was different. Regarding the different bio-
logical characteristics and pathogenesis of each subtype of T/NK-
cell lymphoma, NOVA1 expression may be affected by various 
intrinsic biological factors related to each subtype. The AITL, 
ALK-negative ALCL, and T-LBL subtypes, which showed dis-
tinctively high NOVA1 expression, are biologically characteris-
tic entities.11 Interestingly, the NOVA1 expression pattern was 
different even within ALCL specimens, according to ALK ex-
pression status. ALK-negative ALCL showed distinctively high 
NOVA1 expression while ALK-positive ALCL exhibited low 
NOVA1 expression. Both types of ALCL share common mor-
phologic features of CD30 positivity, large anaplastic “hallmark” 
cells, frequent loss of pan-T-cell antigens, and expression of cyto-
toxic molecules, and are classified as the same disease. However, 
ALK-positive ALCL and ALK-negative ALCL are thought to be 
different entities; the clinical features, prognosis, and gene ex-
pression signatures have been noted to be different.11 Therefore, 
the differences in NOVA1 expression may be related to the in-
trinsic biologic characteristics of these two types. There are no 
known studies that can explain the distinctively low NOVA1 
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Fig. 4. Neuro-oncological ventral antigen 1 (NOVA1) mRNA ex-
pression in various cell lines. NOVA1 mRNA are expressed only in 
Jurkat cell lines, which correspond to T lymphoblastic leukemia/
lymphoma. NOVA1 mRNA are not detected in other tested cell 
lines of HH, MAC1, SNK6, YT, or Toledo.
Fig. 3. Neuro-oncological ventral antigen 1 (NOVA1) expression in B-cell lymphomas. (A, B) In the representative cases of diffuse large B-cell 
lymphoma (DLBCL), almost all tumor cells are negative for NOVA1. In some DLBCL cases, NOVA1-expressing fibroblasts/stromal support 
cells are occasionally found throughout the microenvironment (arrow in panel B). (C, D) In cases of mantle cell lymphoma (MCL) or follicular 
lymphoma (FL), tumor cells are negative for NOVA1, and fibroblasts/stromal support cells are positive for NOVA1 (arrow).
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B
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DLBCL DLBCL
FLMCL
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expression in ALK-positive ALCL. We thought that nucleo-
phosmin (NPM), the fusion partner of ALK-NPM translocation/
t(2;5) in ALK-positive ALCLs, may be associated. NPM is a 
putative ribosome assembly factor involved in processing pre-
RNA molecules.13 Mutated NPM molecules are abnormally lo-
calized in the cytoplasm because of impaired nuclear localiza-
tion, and this abnormal localization of NPM is thought to be 
associated with abnormal ribosome biogenesis.13 The aberrant 
function of mutated NPM may be related to inhibiting 
NOVA1 function in the splicing process of pre-RNA molecules 
via abnormal ribosome biogenesis. PTCL-NOS showed a rela-
tively diverse pattern of NOVA1 expression. The proportion of 
cases showing an intermediate level of NOVA1 expression was 
relatively higher than that in other subtypes. This difference 
may be because PTCL-NOS is a disease group of heterogeneous 
entities of mature (peripheral) T-cell lymphomas. 
NOVA1 expression did not vary according to the organ site 
where the lymphoma developed. These findings indicate that 
NOVA1 expression may be primarily dependent on the intrin-
sic characteristics of the tumor cell itself rather than extrinsic 
factors such as the organ-specific microenvironment, which is 
pre-formed before tumor growth. In association with patient 
prognosis, NOVA1 expression showed no statistical significance. 
However, in mature (peripheral) T-cell lymphomas, high NOVA1 
expression tended to be related to an inferior overall survival rate. 
In our previous study, high NOVA1 expression levels in reactive, 
non-neoplastic (mature) T cells, which accumulate within the 
tertiary lymphoid structures of gastric carcinoma microenviron-
ment, were associated with favorable patient prognosis. Sup-
pression of NOVA1 in such reactive T cells was related with poor 
patient prognosis, and this effect is thought to be related to the 
suppression of regulatory T cell functions.6 From these findings, 
the role of NOVA1 in tumor T cells of malignant lymphomas and 
non-tumor T cells of tissues seems to be different. In normal 
physiologic conditions, NOVA1 upregulation seems to be in-
volved in normal immune regulation. In neoplastic T cells, how-
ever, NOVA1 upregulation seems to be involved in tumor pro-
gression. 
Alternative splicing of pre-mRNA is the main mechanism of 
transcriptome and proteome diversity,4,14 and the splicing pro-
gram relies on the action of splicing factors1 like NOVA1. The 
action of splicing factors is cell type-specific and independent of 
organ origin.2,3,5 Previous studies have suggested or shown that 
normal and tumorous hematopoietic cells are regulated by spe-
cific alternative splicing programs and alternative transcript vari-
ants such as c-myb, a transcription factor of hematopoietic cells; 
CD45, a transmembrane protein tyrosine phosphatase of T cells, 
B cells, and other hematopoietic cells; and CD20, a surface mark-
er of mature B cells.15-17 Likewise, NOVA1 may work as an alter-
native splicing factor in the lymphoreticular system and in lym-
phomagenesis of T/NK-cell lineage. 
Among the tested cell lines, only Jurkat cells, which corre-
sponded to immature T cells, expressed the NOVA1 gene. These 
findings could partially support the findings observed in clinical 
patient samples. The functional role of NOVA1 in lymphoid 
cells and target genes regulated by NOVA1 in lymphomagene-
sis should be identified through further studies. 
In summary, NOVA1 was frequently upregulated in various 
subtypes of T/NK-cell lymphomas. NOVA1 expression may be 
a new biomarker for T/NK-cell lymphomas and should be stud-
ied as a possible therapeutic target for this type of lymphoma. 
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Fig. 5. Patient overall survival according to neuro-oncological ventral antigen 1 (NOVA1) expression in peripheral T-cell lymphoma, not other-
wise specified; three-tiered (A) and two-tiered (B) analysis by Kaplan-Meier with log-rank test. High expression of NOVA1 tends to be related 
to shorter overall survival than low or intermediate expression, although statistical significance is not observed.
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Appendix 1. Clinicopathological characteristics of T/NK-cell lymphoma cases
Characteristic No. (%) (n = 139)
Sex (male vs female) 94 (67.1):45 (32.9)
Age (< 60 yr vs ≥ 60 yr) 91 (65.0):49 (35.0)
Subtype
NKTL 45 (32.4)
PTCL 38 (27.3)
AITL 14 (10.1)
ALCL, ALK-negative 12 (8.6)
ALCL, ALK-positive 12 (8.6)
T-LBL 15 (10.8)
Others 3 (2.2)
Primary site of tumor
H&N vs LN vs GI vs soft tissue and bone vs others (solid organs) 37 (26.4):72 (51.4):9 (6.4):14 (10.0):8 (5.7)
Ann Arbor stage (I & II vs III&IV vs not evaluable) 29 (27.9):77 (55.0):34 (24.3)
LDH level (normal vs elevated vs not evaluable) 39 (27.9):60 (42.9):41 (29.3)
BM involvement (absent vs present vs not evaluable) 77 (55.0):33 (23.6):30 (21.4)
IPI score (0–2 vs 3–5 vs not evaluable) 65 (46.4):43 (30.7):32 (22.9)
Initial treatment modality
CTx alone vs CTx with RTx vs RTx alone vs no Tx vs not evaluable 63 (45.0):27 (19.3):1 (0.7):1 (0.7):48 (34.3)
NK, natural killer; NKTL, extranodal natural killer/T-cell lymphoma, nasal type; PTCL, peripheral T-cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; 
ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; T-LBL, T lymphoblastic leukemia/lymphoma; H&N, head and neck; LN, lymph node; 
GI, gastrointestinal tract; LDH, lactate dehydrogenase; BM, bone marrow; IPI, International Prognostic Index; CTx, chemotherapy; RTx, radiotherapy; Tx, 
treatment.
Appendix 2. List of primary antibodies and their dilutions
Antibody Dilution Type Company
CD20 1:1600 Mouse DAKO, Glostrup, Denmark
CD3 1:200 Rabbit LabVision, Fremont, CA, USA
CD4 1:200 Rabbit Cell Marque, Rocklin, CA, USA
CD8 1:100 Mouse Cell Marque, Rocklin, CA, USA
CD56 1:200 Rabbit Cell Marque, Rocklin, CA, USA
Appendix 3. Neuro-oncological ventral antigen 1 (NOVA1). NOVA1 protein expression in various organ/sites of lymphomas. NOVA1 expres-
sion level in tumor cells does not vary according to the organ/sites where lymphomas were growing. GI, gastrointestinal.
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